Samsung Biologics Posts 586.4 Billion Won Q2 Profit, But Labor Uncertainty Looms
Samsung Biologics reported second-quarter revenue in the 1. 3 trillion won range this year, a 30% increase from the same period last year.
Biowatch
117 Workplace Accidents Recognized at 25 Major Korean Pharma and Biotech Firms Over Five Years
A review of 25 major South Korean pharmaceutical and biotechnology companies revealed 117 recognized industrial accidents over the past five years.
Biogen Korea Taps Pharma Veteran Kim Chul-woong as New Country Lead
Biogen Korea has appointed Kim Chul-woong as its new general manager, tapping an executive with extensive expertise in...
Samsung Biologics Bets 2.7 Trillion Won on Peptides in South Korea’s Largest Biotech M&A Deal
Samsung Biologics is making a major push into peptide-based medicines—widely used in weight-loss and diabetes...
Novo Nordisk Secures EU Green Light for Oral Wegovy, Outpacing Eli Lilly in the Pill Market
The glucagon-like peptide-1 (GLP-1) obesity treatment market, long dominated by subcutaneous injections, is rapidly...
Deceptive Symptoms in Diagnostic Gaps: 88% of Pediatric Pneumonia Cases Coincide with Viruses
Diagnosing respiratory infections in infants and toddlers using virus-only testing can leave dangerous diagnostic gaps,...
31 Bottles Per Person: Kwangdong Corn Silk Tea Marks 20th Anniversary With 1.6 Billion Bottles Sold
For South Koreans looking for a refreshing, caffeine-free beverage, it is a staple that almost everyone has tried at...
Anchoring the U.S. Supply Chain: GC Green Cross Expands 30-Year Cytiva Partnership to Secure Alyglo Production
GC Green Cross has secured priority access to critical manufacturing consumables to stabilize the production of Alyglo,...
Celltrion Secures South Korean Phase 1 Approval for Tremfya Biosimilar CT-P68
Celltrion announced on July 15 that it has received approval from South Korea’s Ministry of Food and Drug Safety for an...
Fast-Tracking Biosimilars: South Korea to Waive Phase 3 Clinical Trials Under New Guidelines
South Korean regulators have revised requirements to significantly reduce the time and financial burden of biosimilar...